“Taking Tylenol during pregnancy causes autism in children.”

• Numerous observational cohort studies have reported modest statistical associations between prenatal acetaminophen (paracetamol/Tylenol) exposure and later diagnoses of autism spectrum disorder or ADHD. Examples include analyses of the Danish National Birth Cohort and the Norwegian MoBa cohort, with pooled meta-analyses typically reporting risk ratios in the ~1.2–1.3 range for ADHD and somewhat weaker for ASD.
• A 2020 JAMA Psychiatry study (Ji et al., Boston Birth Cohort) measured acetaminophen and its metabolites directly in umbilical cord plasma — an objective biomarker rather than maternal recall — and found higher biomarker levels associated with increased odds of later ADHD and ASD diagnoses, with an apparent dose-response gradient.
• In 2021, a consensus statement in Nature Reviews Endocrinology signed by 91 clinicians and scientists argued the cumulative evidence warranted 'precautionary action' — use at the lowest effective dose for the shortest time — citing experimental and mechanistic data on acetaminophen as a possible endocrine disruptor and source of oxidative stress in the developing brain.
• Animal and in-vitro work provides some biological plausibility: acetaminophen crosses the placenta, depletes glutathione, and has been shown in rodent models to affect neurodevelopmental and behavioral endpoints.
• In September 2025, HHS/FDA publicly announced a label-change initiative for acetaminophen referencing studies of prenatal exposure and neurodevelopmental outcomes, which gave the association official-sounding endorsement in the U.S. (though the FDA's own notice stated a causal relationship had not been established).

• The single largest and methodologically strongest study — Ahlqvist et al., JAMA 2024, covering 2.48 million Swedish children — found the crude association vanished in sibling-control analysis. Comparing exposed and unexposed siblings from the same mother (which holds genetics and family environment constant), the hazard ratio for autism was ~0.98, i.e., no association. This pattern is the classic signature of confounding, not causation.
• Earlier sibling-control and negative-control analyses (including Norwegian MoBa and Japanese cohort work) show the same attenuation toward null, indicating the raw associations largely reflect shared familial factors.
• Confounding by indication is severe and hard to remove: the reasons women take acetaminophen — fever, infection, inflammation, chronic pain, migraine — are themselves independently linked to adverse neurodevelopmental outcomes. Maternal pain/fever/infection, not the drug, may carry the risk.
• Autism is strongly heritable (twin and family studies put heritability around 60–90%). Mothers with neurodevelopmental or chronic-pain conditions both use more analgesics and are more likely to have autistic children — a genetic pathway that non-sibling designs cannot separate out.
• No randomized controlled trial supports causation, and no study has demonstrated the Bradford Hill criteria (consistency, specificity, temporality with dose, biological gradient that survives confounding control) for an acetaminophen–autism causal link.
• Major professional bodies — ACOG, the Society for Maternal-Fetal Medicine, and counterpart bodies in the UK (MHRA/NHS) and EU (EMA, which completed a review finding no change warranted) — state that acetaminophen remains the safest available analgesic/antipyretic in pregnancy and that the evidence does not establish causation.
• Untreated maternal fever is itself associated with neural tube defects, miscarriage and adverse neurodevelopmental outcomes, and the main alternatives (NSAIDs) are contraindicated in much of pregnancy. A blanket causal claim carries real potential for harm.
• The documented rise in autism prevalence is substantially explained by broadened diagnostic criteria (DSM changes), screening expansion, and increased service-linked identification, per CDC ADDM surveillance — it does not track acetaminophen sales in a way that implies causation.

88/100 — the lab’s own confidence in the score above, not a second reading of the claim.

JAMA (Ahlqvist et al., 2024 — Swedish 2.48M sibling-control cohort)journal · 96 · PubMed / National Library of Medicine (record for Ahlqvist et al., JAMA 2024)gov · 95 · JAMA Psychiatry (Ji et al., 2020 — cord-plasma biomarker study; evidence FOR)journal · 88 · Nature Reviews Endocrinology (2021 consensus statement calling for precautionary action)journal · 85 · NHS (UK) — paracetamol in pregnancy guidancegov · 88 · U.S. Centers for Disease Control and Prevention — autism prevalence/ADDM datagov · 93

• Tylenol is acetaminophen, also called paracetamol. Some observational studies have reported associations between prenatal acetaminophen exposure and later autism-related outcomes, especially with higher or longer exposure. For example, a 2019 JAMA Psychiatry study using cord-blood biomarkers in the Boston Birth Cohort found higher measured acetaminophen exposure was associated with higher odds of later ASD and ADHD diagnoses.
• A 2016 International Journal of Epidemiology cohort study reported that prenatal acetaminophen use was associated with more autism-spectrum symptoms in boys and more attention-related symptoms overall.
• A 2021 Nature Reviews Endocrinology consensus statement argued that epidemiologic and experimental evidence was sufficient to recommend precautionary use during pregnancy, though it did not prove acetaminophen causes autism.

• The claim says acetaminophen causes autism. The strongest available human evidence does not establish causation. Many earlier positive studies were observational and vulnerable to confounding by the reasons acetaminophen was taken, such as fever, infection, pain, migraine, inflammation, genetics, parental neurodevelopmental traits, and other shared family factors.
• A very large 2024 JAMA Swedish nationwide sibling-control study of about 2.48 million children found that conventional models showed small associations, but these disappeared in sibling comparisons: sibling-control analyses did not support a causal link between prenatal acetaminophen use and autism, ADHD, or intellectual disability.
• The FDA has reviewed studies on pain-medicine use in pregnancy and stated that available evidence on acetaminophen and neurodevelopmental outcomes was inconclusive, not proof of causation.
• ACOG states that no clear evidence proves a direct relationship between prudent acetaminophen use during pregnancy and fetal developmental problems, and it continues to regard acetaminophen as an important option when medically needed.
• Overall, the accurate statement would be that some studies found correlations and researchers have investigated a possible risk; the stronger statement that taking Tylenol during pregnancy causes autism is not supported by the best evidence.

90/100 — the lab’s own confidence in the score above, not a second reading of the claim.

JAMAjournal · 97 · JAMA Psychiatryjournal · 94 · International Journal of Epidemiologyjournal · 91 · Nature Reviews Endocrinologyjournal · 93

• Some observational cohort studies over the last decade have identified a statistical correlation between prenatal exposure to acetaminophen (the active ingredient in Tylenol) and a moderately increased rate of neurodevelopmental conditions like autism spectrum disorder (ASD) and ADHD in children.
• In 2021, a consensus statement by a group of international scientists and medical professionals published in Nature Reviews Endocrinology highlighted these observational associations. The authors called for precautionary action, recommending that pregnant women minimize acetaminophen use unless medically indicated.

• Major medical organizations, including the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM), have consistently rejected the claim that Tylenol causes autism. They emphasize that observational studies cannot prove causation due to significant confounding factors, such as maternal genetics, family environment, and the underlying indications for taking the medication (e.g., untreated high maternal fever, which is a known risk factor for fetal neurodevelopmental issues).
• A rigorous, definitive 2024 nationwide cohort study published in JAMA utilized sibling-control analyses to account for unmeasured genetic and environmental variables. When comparing siblings with different prenatal exposures to acetaminophen, researchers found no evidence of an increased risk of autism, ADHD, or intellectual disability, concluding that earlier reported correlations were the result of familial confounding.
• In December 2023, a U.S. federal judge dismissed a massive multidistrict litigation (MDL) involving thousands of lawsuits alleging that Tylenol caused autism. The judge ruled that the plaintiffs' expert witnesses failed to meet the Daubert standard for admissibility, stating there was no scientifically sound evidence or reliable methodology to prove a causal link.

98/100 — the lab’s own confidence in the score above, not a second reading of the claim.

JAMAjournal · 95 · Reutersnews · 95 · Nature Reviews Endocrinologyjournal · 90

• Several observational studies and reviews have reported a statistical association between prenatal acetaminophen exposure and autism diagnoses, particularly with prolonged or repeated use. A 2026 meta-analysis of eight observational studies involving about 2.56 million participants reported an 18% higher odds of autism diagnosis, though this evidence is observational and cannot establish causation.[2]
• The U.S. Food and Drug Administration states that an association has been reported in multiple studies and that some studies suggest the association may be strongest with chronic use throughout pregnancy; however, it explicitly says causality has not been established and that contrary studies exist.[3][5]

• The claim says acetaminophen causes autism, but available evidence does not establish a causal relationship. The FDA describes the issue as an association under scientific debate and notes contrary findings.[3][5]
• The World Health Organization says there is currently no conclusive scientific evidence confirming a link and that no consistent association has been established.[1]
• A systematic review focused on sibling-comparison and other lower-bias studies found no association between prenatal acetaminophen exposure and autism, ADHD, or intellectual disability; it concluded that high-quality evidence does not support an association.[6]
• An umbrella review covering more than 3 million mother-child pairs found that small associations weakened or disappeared in the highest-quality, lowest-bias analyses, with confounding by pain, fever, infection, and measurement limitations likely explaining at least part of the apparent association.[4]
• Even if some observational studies show increased risk, they cannot by themselves distinguish an effect of acetaminophen from the illnesses or other factors for which it was taken. The evidence therefore does not support the categorical statement that taking Tylenol during pregnancy causes autism.[1][3][4]

93/100 — the lab’s own confidence in the score above, not a second reading of the claim.

World Health Organizationgov · 98 · National Library of Medicine / peer-reviewed systematic review and meta-analysisjournal · 75 · U.S. Food and Drug Administrationgov · 97 · Developmental Medicine & Child Neurology / umbrella reviewjournal · 88 · U.S. Food and Drug Administrationgov · 97 · Anesthesia Patient Safety Foundationother · 78

• Several observational cohort studies (Norway, Denmark, U.S. and others) have reported statistical associations between reported acetaminophen use in pregnancy and higher rates of autism or ADHD diagnoses.
• A 2021 consensus statement by 91 scientists in Nature Reviews Endocrinology urged precautionary limits on acetaminophen in pregnancy, citing possible fetal neurodevelopmental effects.
• Limited animal and mechanistic studies have suggested acetaminophen can influence brain development pathways.

• A 2024 nationwide Swedish sibling-comparison study of 2.48 million children (JAMA) found no increased risk of autism, ADHD or intellectual disability after controlling for familial confounding, indicating earlier associations were likely spurious.
• The U.S. FDA reviewed the literature in 2015, found the data inconclusive, and has not advised against acetaminophen use in pregnancy.
• ACOG, SMFM and other obstetric authorities continue to recommend acetaminophen as the preferred analgesic/antipyretic because untreated fever and pain themselves raise risks, and no causal human mechanism has been demonstrated.
• Autism is predominantly genetic; indication confounding (infection, inflammation, pain) and recall bias readily explain non-sibling observational links.

85/100 — the lab’s own confidence in the score above, not a second reading of the claim.

JAMAjournal · 95 · Nature Reviews Endocrinologyjournal · 85